P120008/S032: ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)
FDA’s recorded scope: Approval of changes in testing requirements of reference materials.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 7 FDA records to the applicant name ABBOTT LABORATORIES. The collection includes 2 510(k) clearances. 5 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Feb 12, 2026 to Sep 23, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code LOK appears in 2 of the 7 linked filings. The collection spans 4 FDA product codes and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P120008, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 100 Abbott Park Rd., Cp1, Abbott Park, IL, 60064, US. Recorded on K262156, decision dated Sep 23, 2026.
Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus; Kit, Test, Alpha-Fetoprotein For Neural Tube Defects; Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer; Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions.
FDA’s recorded scope: Approval of changes in testing requirements of reference materials.
FDA’s recorded scope: Update panel testing specifications.
FDA’s recorded scope: change to a new supplier of a manufacturing ingredient
FDA’s recorded scope: change to a new supplier of a manufacturing ingredient
FDA’s recorded scope: change to a new supplier of a manufacturing ingredient
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
MedtechLedger links 7 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 7 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.
| Recall / product | Company | Classification | Report date | Source |
|---|---|---|---|---|
| ABBOTT LABORATORIES | Class II | Dec 24, 2025 | FDA | |
| ABBOTT LABORATORIES | Class II | Nov 19, 2025 | FDA | |
| ABBOTT LABORATORIES | Class II | Apr 30, 2025 | FDA | |
| ABBOTT LABORATORIES | Class II | Apr 30, 2025 | FDA | |
| ABBOTT LABORATORIES | Class II | Apr 30, 2025 | FDA | |
| ABBOTT LABORATORIES | Class II | Apr 30, 2025 | FDA |
Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.
Search the firm’s recall recordsSource updated Nov 11, 2026. Retrieved Nov 20, 2026.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Anti-HCV NextK262156 | ABBOTT LABORATORIES | 510(k) clearance | Sep 23, 2026 | FDA |
ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)P120008/S032 | ABBOTT LABORATORIES | PMA supplement | May 11, 2026 | FDA |
Anti-HCV NextK252424 | ABBOTT LABORATORIES | 510(k) clearance | Apr 28, 2026 | FDA |
| ABBOTT LABORATORIES | PMA supplement | Feb 23, 2026 | FDA | |
ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)P120008/S031 | ABBOTT LABORATORIES | PMA supplement | Feb 12, 2026 | FDA |
| ABBOTT LABORATORIES | PMA supplement | Feb 12, 2026 | FDA | |
| ABBOTT LABORATORIES | PMA supplement | Feb 12, 2026 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 20, 2026.